Related Experiment Videos

Third-party reimbursement issues during a phase I trial of interleukin-2

N J Vogelzang, J M Richards

Journal of the National Cancer Institute

|April 5, 1989

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

BMC cancer·2021

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Cancer treatment and research communications·2019

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

See all related articles